Effects of AST-120 on left ventricular mass in predialysis patients

American Journal of Nephrology

Volumn 33, Issue 3, 2011, Pages 218-223

  Nakai, Kentaro ^a   Fujii, Hideki ^a   Kono, Keiji ^a   Goto, Shunsuke ^a   Fukagawa, Masafumi ^a,b   Nishi, Shinichi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY   (Japan)

Author keywords

AST 120; Left ventricular concentric change; Predialysis chronic kidney disease

Indexed keywords

ALBUMIN; ANGIOTENSIN ANTAGONIST; AST 120; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM; CREATININE; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PARATHYROID HORMONE; PHOSPHORUS; PROTEIN; SERUM ALBUMIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BIOCHEMICAL COMPOSITION; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE URINE LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIALYSIS; DISEASE ASSOCIATION; DRUG USE; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE SIZE; HEART LEFT VENTRICLE WALL; HEART PROTECTION; HEART VENTRICLE SEPTUM; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PREDIALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PULSE PRESSURE; SEX DIFFERENCE; TREATMENT DURATION; TWO DIMENSIONAL ECHOCARDIOGRAPHY; UREA NITROGEN BLOOD LEVEL;

CARBON; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIALYSIS; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; FEMALE; HEART VENTRICLES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; OXIDES;

EID: 79951560857     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000324354     Document Type: Article

References (33)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
2. Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, Wakugawa Y, Hata J, Oi-shi Y, Shikata K, Yonemoto K, Hirakata H, Iida M: Chronic kidney disease and cardio-vascular disease in a general Japanese popu-lation: the Hisayama Study. Kidney Int 2005; 68:228-236. (Pubitemid 43181380)
3. Nakayama M, Metoki H, Terawaki H, Oh-kubo T, Kikuya M, Sato T, Nakayama K, Asayama K, Inoue R, Hashimoto J, Totsune K, Hoshi H, Ito S, Imai Y: Kidney dysfunc-tion as a risk factor for first symptomatic stroke events in a general Japanese popula-tion-the Ohasama study. Nephrol Dial Transplant 2007; 22: 1910-1915. (Pubitemid 47244759)
4. Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G: Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis 2005; 46:320-327. (Pubitemid 41040362)
5. Moran A, Katz R, Jenny NS, Astor B, Bluemke DA, Lima JA, Siscovick D, Bertoni AG, Shlipak MG: Left ventricular hypertrophy in mild and moderate reduction in kidney function determined using cardiac magnetic resonance imaging and cystatin C: the multi-ethnic study of atherosclerosis (MESA). Am J Kidney Dis 2008; 52: 839-848.
6. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE: Outcome and risk fac-tors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996; 11: 1277-1285. (Pubitemid 26241416)
7. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barré PE: The prognostic im-portance of left ventricular geometry in ure-mic cardiomyopathy. J Am Soc Nephrol 1995; 5: 2024-2031.
8. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, Vanholder R, Massy ZA, European Uremic Toxin Work Group (EUTox): Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease pa-tients. Clin J Am Soc Nephrol 2009; 4:1551-1558.
9. Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, Fukuhara S, Gejyo F, Matsuo S, Yorioka N, Kurokawa K, CAP-KD Study Group: Effect of a carbonaceous oral adsor-bent on the progression of CKD: a multi-center, randomized, controlled trial. Am J Kidney Dis 2009; 54:459-467.
10. Shimoishi K, Anraku M, Kitamura K, Tasaki Y, Taguchi K, Hashimoto M, Fukunaga E, Maruyama T, Otagiri M: An oral adsorbent, AST-120 protects against the progression of oxidative stress by reducing the accumula-tion of indoxyl sulfate in the systemic circu-lation in renal failure. Pharm Res 2007; 24: 1283-1289. (Pubitemid 46870593)
11. Nakagawa N, Hasebe N, Sumitomo K, Fujino T, Fukuzawa J, Hirayama T, Kikuchi K: An oral adsorbent, AST-120, suppresses oxida-tive stress in uremic rats. Am J Nephrol 2006; 26: 455-461. (Pubitemid 44971736)
12. Yamakado M, Ise M: Mechanism of oral ab-sorbent AST-120 in lipid abnormalities in ex-perimental uremic rats. Kidney Int Suppl 1999; 71:S190-S192. (Pubitemid 29304849)
13. Ueda S, Yamagishi S, Takeuchi M, Kohno K Shibata R, Matsumoto Y, Kaneyuki U, Fu-jimura T, Hayashida A, Okuda S: Oral adsor-bent AST-120 decreases serum levels of AGEs in patients with chronic renal failure. Mol Med 2006; 12: 180-184. (Pubitemid 44646347)
14. Fujii H, Nishijima F, Goto S, Sugano M, Ya-mato H, Kitazawa R, Kitazawa S, Fukagawa M: Oral charcoal adsorbent (AST-120) pre-vents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant 2009; 24:2089-2095.
15. Sahn DJ, DeMaria A, Kisslo J, Weyman A: Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083. (Pubitemid 9091990)
16. Devereux RB, Alonso DR, Lutas EM, Gott-lieb GJ, Campo E, Sachs I, Reichek N: Echo-cardiographic assessment of left ventricular hypertrophy: comparison to necropsy find-ings. Am J Cardiol 1986; 57: 450-458. (Pubitemid 16119719)
17. Nakamura T, Sato E, Fujiwara N, Kawagoe Y Suzuki T, Ueda Y, Yamagishi SI: Oral adsor-bent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation. Metabolism 2011; 60: 260-264.
18. Wachtell K, Bella JN, Liebson PR, Gerdts E, Dahlöf B, Aalto T, Roman MJ, Papademe-triou V, Ibsen H, Rokkedal J, Devereux RB: Impact of different partition values on prev-alences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE study. Hypertension 2000; 35: 6-12. (Pubitemid 30054229)
19. Grossman W, Jones D, McLaurin LP: Wall stress and patterns of hypertrophy in the hu-man left ventricle. J Clin Invest 1975; 56: 56-64.
20. Glassock RJ, Pecoits-Filho R, Barberato SH: Left ventricular mass in chronic kidney dis-ease and ESRD. Clin J Am Soc Nephrol 2009; 4:S79-S91.
21. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, Mc-Cullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: American Heart Association Councils on Kidney in Cardiovascular Dis-ease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preven-tion: Kidney disease as a risk factor for devel-opment of cardiovascular disease: a state-ment from the American Heart Association Councils on Kidney in Cardiovascular Dis-ease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preven-tion. Circulation 2003; 108:2154-2169.
22. Amann K, Rychlík I, Miltenberger-Milteny G, Ritz E: Left ventricular hypertrophy in renal failure. Kidney Int Suppl 1998; 68:S78-S85. (Pubitemid 28531781)
23. Galderisi M, Anderson KM, Wilson PW, Levy D: Echocardiographic evidence for the existence of a distinct diabetic cardiomyopa-thy (the Framingham Heart Study). Am J Cardiol 1991; 68: 85-89.
24. Grossman E, Shemesh J, Shamiss A, Thaler M, Carroll J, Rosenthal T: Left ventricular mass in diabetes-hypertension. Arch Intern Med 1992; 152: 1001-1004.
25. Ohya Y, Abe I, Fujii K, Ohmori S, Onaka U, Kobayashi K, Fujishima M: Hyperinsu-linemia and left ventricular geometry in a work-site population in Japan. Hypertension 1996; 27:729-734. (Pubitemid 26086238)
26. Ilercil A, Devereux RB, Roman MJ, Parani-cas M, Ogrady MJ, Welty TK, Robbins DC, Fabsitz RR, Howard BV, Lee ET: Relation-ship of impaired glucose tolerance to left ventricular structure and function: The Strong Heart Study. Am Heart J 2001; 141: 992-998. (Pubitemid 32477012)
27. Amann K, Ritz E, Wiest G, Klaus G, Mall G: A role of parathyroid hormone for the activa-tion of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994; 4: 1814-1819.
28. Pecoits-Filho R, Lindholm B, Stenvinkel P: The malnutrition, inflammation, and ath-erosclerosis (MIA) syndrome-the heart of the matter. Nephrol Dial Transplant 2002; 17: 28-31.
29. Fujii H, Kim JI, Abe T, Umezu M, Fukagawa M: Relationship between parathyroid hor-mone and cardiac abnormalities in chronic dialysis patients. Intern Med 2007; 46:1507-1512. (Pubitemid 47521045)
30. Strózecki P, Adamowicz A, Nartowicz E, Odrowaz-Sypniewska G, Włodarczyk Z, Manitius J: Parathormone, calcium, phos-phorus, and left ventricular structure and function in normotensive hemodialysis pa-tients. Ren Fail 2001; 23: 115-126. (Pubitemid 32207300)
31. Koleganova N, Piecha G, Ritz E, Gross ML: Calcitriol ameliorates capillary deficit and fibrosis of the heart in subtotally nephrecto-mized rats. Nephrol Dial Transplant 2009; 24:778-787.
32. Agarwal R, Light RP: Determinants and prognostic significance of electrocardio-graphic left ventricular hypertrophy criteria in chronic kidney disease. Clin J Am Soc Nephrol 2010, Epub ahead of print.
33. McQuarrie EP, Patel RK, Mark PB, Delles C, Connell J, Dargie HJ, Steedman T, Jardine AG: Association between proteinuria and left ventricular mass index: a cardiac MRI study in patients with chronic kidney dis-ease. Nephrol Dial Transplant 2010, Epub ahead of print.